Ortho Regenerative Technologies develops a platform technology for repair and regeneration of damaged joints, including the knee and shoulder. Its core formulations are designed to transform from a freeze-dried polymer into therapeutic microparticles upon contact with surgically prepared lesions or when combined with blood fractions enriched for wound-healing cells. The company intends to build a portfolio of products based on this core technology to regenerate joint tissues. Ortho RTi entered into an agreement with Gestion Univalor, L.P. and Polytechnique Montréal to acquire the underlying platform. Financially, Manitex Capital (MNX:Venture) acquired a 44% equity interest in the company as part of a transaction that included funding. Manitex will provide assistance and documentation to help Ortho RTi obtain regulatory certification and scale commercial production. Steve Saviuk, CEO of Manitex, will serve as interim President of Ortho RTi.

Total raised

$1M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Aug 2015